EUCTR2009-018161-12-IT进行中（未招募）不适用
A phase 3, double-blind, placebo-controlled, multicentre, randomised-withdrawal, long-term maintenance of efficacy and safety study of extended-release Guanfacine Hydrochloride in children and adolescents aged 6-17 with Attention-deficit/Hyperactivity Disorder
Shire Development Inc.0 个研究点目标入组 510 人开始时间: 2011年12月28日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 510
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female, aged 6-17 years at the time of consent/assent at Screening/Visit 1. 2. Subject meets Diagnostic and Statistical Manual of Mental Disorders, 4th ed.-Text Revision (DSM-IV-TR ) criteria for a primary diagnosis of ADHD, combined sub-type, hyperactive/impulsive sub-type, or inattentive sub-type based on a detailed psychiatric evaluation using the Kiddie Schedule for Affective Disorders and Schizophrenia-Present and Lifetime version (K-SADS-PL). 3. Subject has a minimum ADHD-RS-IV total score of 32 at Enrolment/Visit 2. 4. Subject has a minimum CGI-S score of 4 at Enrolment/Visit 2. 5. Subject is able to swallow intact tablets.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Subject has a current, controlled (requiring a prohibited medication or behavioural modification program) or uncontrolled, co-morbid psychiatric diagnosis, except Oppositional Defiant Disorder (ODD), including any severe comorbid Axis II disorders or severe Axis I disorders such as Post Traumatic Stress Disorder, bipolar illness, psychosis, pervasive developmental disorder, obsessive-compulsive disorder, substance abuse disorder, or other symptomatic manifestations or lifetime history of bipolar illness, psychosis, or conduct disorder that, in the opinion of the Investigator, contraindicate SPD503 treatment or confound efficacy or safety assessments. 2. Subject has a known history or presence of structural cardiac abnormalities, serious heart rhythm abnormalities, syncope, cardiac conduction problems (e.g., clinically significant heart block), exercise-related cardiac events including syncope and pre-syncope, or clinically significant bradycardia. 3. Subject with orthostatic hypotension or a known history of controlled or uncontrolled hypertension. 4. Current use of any prohibited medication or other medications, including herbal supplements, that affect blood pressure (BP) or heart rate or that have central nervous system (CNS) effects or affect cognitive performance, such as sedating antihistamines and decongestant sympathomimetics (inhaled bronchodilators are permitted) or a history of chronic use of sedating medications (i.e., antihistamines) in violation of the protocol specified washout criteria at Enrolment/Visit 2. 5. Subject is significantly overweight based on Centre for Disease Control and Prevention Body Mass Index (BMI)-for-age gender specific charts. Significantly overweight is defined as a BMI >95th percentile. 6. Children aged 6-12 years with a body weight of <25.0kg or adolescents aged 13-17 years with a body weight of <34.0kg or >91.0kg at Screening/Visit 1. 7. Subject has a history of alcohol or other substance abuse or dependence, as defined by DSM-IV-TR (with the exception of nicotine) within the last 6 months. 8. Subject is currently considered a suicide risk in the opinion of the Investigator, has previously made a suicide attempt, or has a prior history of, or is currently demonstrating active suicidal ideation. Subjects with intermittent passive suicidal ideation are not necessarily excluded based on the assessment of the Investigator (see protocol for additional guidance). 9. History of failure to respond to an adequate trial of an a2-agonist for the treatment of ADHD (consisting of an appropriate dose and adequate duration of therapy in the opinion of the Investigator).
研究者
相似试验
进行中（未招募）
1 期
Study to assess the long term safety and efficacy of Guanfacine-Hydrochloride in Children and Adolescents aged 6-17 years old, with Attention- Deficit/Hyperactivity DisorderAttention-Deficit/Hyperactive Disorder (ADHD)MedDRA version: 14.1Level: LLTClassification code 10068451Term: ADHD, combined typeSystem Organ Class: 100000004873MedDRA version: 14.1Level: LLTClassification code 10068453Term: ADHD, predominantly inattentive typeSystem Organ Class: 100000004873MedDRA version: 14.1Level: LLTClassification code 10068452Term: ADHD, predominantly hyperactive-impulsive typeSystem Organ Class: 100000004873MedDRA version: 14.1Level: LLTClassification code 10064104Term: ADHDSystem Organ Class: 100000004873EUCTR2009-018161-12-GBShire Development Inc510
进行中（未招募）
不适用
Study to assess the long term safety and efficacy of Guanfacine- Hydrochloride in Children and Adolescents aged 6-17 years old, with Attention- Deficit/Hyperactivity DisorderAttention-Deficit/Hyperactive Disorder (ADHD)MedDRA version: 15.1Level: LLTClassification code 10068451Term: ADHD, combined typeSystem Organ Class: 100000004873MedDRA version: 15.1Level: LLTClassification code 10068453Term: ADHD, predominantly inattentive typeSystem Organ Class: 100000004873MedDRA version: 15.1Level: LLTClassification code 10068452Term: ADHD, predominantly hyperactive-impulsive typeSystem Organ Class: 100000004873MedDRA version: 15.1Level: LLTClassification code 10064104Term: ADHDSystem Organ Class: 100000004873EUCTR2009-018161-12-NLShire Development Inc510
进行中（未招募）
不适用
Study to assess the long term safety and efficacy of Guanfacine-Hydrochloride in Children and Adolescents aged 6-17 years old, withAttention- Deficit/Hyperactivity DisorderEUCTR2009-018161-12-SEShire Development Inc510
已完成
3 期
A Phase 3, Double-blind, Placebo-controlled, Multicentre, Randomised withdrawal, Long-term Maintenance of Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 With Attention deficit/Hyperactivity DisorderADHD10009841Attention Deficit Hyperactivity DisorderNL-OMON39353Shire15
进行中（未招募）
1 期
A Phase 3, Double-blind, Placebo-controlled, Multicentre, Randomised withdrawal, Long-term Maintenance of Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 With Attention deficit/Hyperactivity Disorder Estudio de Fase 3, doble ciego, controlado con placebo, multicéntrico, de mantenimiento a largo plazo y retirada aleatorizada, de la eficacia y seguridad de Clorhidrato de Guanfacina de liberación prolongada en niños y adolescentes de 6 a 17 años con Trastorno por Déficit de Atención con HiperactividadAttention-Deficit/Hyperactive Disorder (ADHD)Trastorno por déficit de atención con hiperactividadMedDRA version: 12.1Level: LLTClassification code 10064104Term: ADHDMedDRA version: 12.1Level: LLTClassification code 10068451Term: ADHD, combined typeMedDRA version: 12.1Level: LLTClassification code 10068452Term: ADHD, predominantly hyperactive-impulsive typeMedDRA version: 12.1Level: LLTClassification code 10068453Term: ADHD, predominantly inattentive typeEUCTR2009-018161-12-ESShire Development Inc528